Discounted Cash Flow (DCF) Analysis Levered
Intellia Therapeutics, Inc. (NTLA)
$31.62
-0.14 (-0.44%)
All numbers are in Millions, Currency in USD
Free Cash Flow
Year A/P | 2018 Actual | 2019 Actual | 2020 Actual | 2021 Actual | 2022 Actual | 2023 Projected | 2024 Projected | 2025 Projected | 2026 Projected | 2027 Projected |
| Revenue | 30.43 | 43.10 | 57.99 | 33.05 | 52.12 | 63.96 | 78.49 | 96.32 | 118.19 | 145.04 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (%) | ||||||||||
| Operating Cash Flow | -61.26 | -103.24 | -49.91 | -225.03 | -333.29 | -236.28 | -289.96 | -355.82 | -436.64 | -535.82 |
| Operating Cash Flow (%) | ||||||||||
| Capital Expenditure | -6.36 | -6.79 | -3.59 | -12.76 | -58.39 | -24.75 | -30.37 | -37.27 | -45.73 | -56.12 |
| Capital Expenditure (%) | ||||||||||
| Free Cash Flow | -67.62 | -110.03 | -53.50 | -237.79 | -391.68 | -261.03 | -320.32 | -393.08 | -482.37 | -591.94 |
Weighted Average Cost Of Capital
| Share price | $ 31.62 |
|---|---|
| Beta | 1.836 |
| Diluted Shares Outstanding | 76.97 |
| Cost of Debt | |
| Tax Rate | -3.38 |
| After-tax Cost of Debt | 6.54% |
| Risk-Free Rate | |
| Market Risk Premium | |
| Cost of Equity | 13.239 |
| Total Debt | 130.70 |
| Total Equity | 2,433.85 |
| Total Capital | 2,564.56 |
| Debt Weighting | 5.10 |
| Equity Weighting | 94.90 |
| Wacc |
Build Up Free Cash Flow
Year A/P | 2018 Actual | 2019 Actual | 2020 Actual | 2021 Actual | 2022 Actual | 2023 Projected | 2024 Projected | 2025 Projected | 2026 Projected | 2027 Projected |
| Revenue | 30.43 | 43.10 | 57.99 | 33.05 | 52.12 | 63.96 | 78.49 | 96.32 | 118.19 | 145.04 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -61.26 | -103.24 | -49.91 | -225.03 | -333.29 | -236.28 | -289.96 | -355.82 | -436.64 | -535.82 |
| Capital Expenditure | -6.36 | -6.79 | -3.59 | -12.76 | -58.39 | -24.75 | -30.37 | -37.27 | -45.73 | -56.12 |
| Free Cash Flow | -67.62 | -110.03 | -53.50 | -237.79 | -391.68 | -261.03 | -320.32 | -393.08 | -482.37 | -591.94 |
| WACC | ||||||||||
| PV LFCF | -231.21 | -251.30 | -273.15 | -296.90 | -322.71 | |||||
| SUM PV LFCF | -1,375.26 |
Terminal Value
| Growth in perpetuity method: | |
|---|---|
| Long-term growth rate | |
| WACC (%) | 12.90 |
| Free cash flow (t + 1) | -603.78 |
| Terminal Value | -5,539.25 |
| Present Value of Terminal Value | -3,019.82 |
Intrinsic Value
| Enterprise Value | -4,395.09 |
|---|---|
| Net Debt | -392.80 |
| Equity Value | -4,002.28 |
| Shares Outstanding | 76.97 |
| Equity Value Per Share | -52.00 |